GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Oncology/Advanced Adenomas Detected Frequently in Young Endurance Runners : Cancer Epidemiol | May 2026
72

Advanced Adenomas Detected Frequently in Young Endurance Runners : Cancer Epidemiol | May 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated May 1, 2026

Introduction

Regular physical activity is generally associated with reduced colorectal cancer (CRC) risk. However, extreme endurance exercise may produce repetitive gastrointestinal stress through splanchnic hypoperfusion, ischemia–reperfusion injury, mucosal inflammation and occult gastrointestinal bleeding. Whether chronic exposure to these physiologic insults influences colorectal neoplasia risk remains poorly understood.

Problem Statement

Although gastrointestinal bleeding and ischemic colitis are recognized complications of endurance running, data linking high-volume endurance exercise with colorectal adenomas or advanced neoplasia are lacking. Understanding whether endurance athletes harbor increased rates of premalignant colorectal lesions could influence screening and evaluation strategies, particularly in younger individuals with post-exercise rectal bleeding.

Summary

This prospective hypothesis-generating study evaluated colonoscopic findings in endurance runners aged 35–50 years with substantial marathon or ultramarathon exposure. Adenomas were identified in over 40% of participants, while advanced adenomas were detected in 15%, substantially exceeding historical screening benchmarks for average-risk younger adults. Importantly, no colorectal cancers were identified. Most advanced lesions were right-sided and frequently exhibited high-risk features including large size, tubulovillous histology or sessile serrated morphology. Post-exercise rectal bleeding was significantly more common among runners with advanced adenomas, suggesting that gastrointestinal bleeding after endurance exercise should not be routinely dismissed as benign “runner’s colitis.” Notably, advanced adenomas were also detected in asymptomatic runners without bleeding, indicating that clinically silent lesions may occur in this population. Despite the observed adenoma burden, the study did not demonstrate a clear relationship between training intensity and lesion prevalence, underscoring the exploratory nature of the findings. The authors propose several biologically plausible mechanisms including repetitive ischemia–reperfusion injury, oxidative stress, microbiome alterations and mucosal regenerative hyperproliferation. However, the study’s single-arm design, modest sample size and potential selection bias preclude causal inference. Overall, the findings generate an important hypothesis that extreme endurance running may be associated with increased prevalence of advanced colorectal precursor lesions and support larger controlled studies evaluating colorectal neoplasia risk in endurance athletes.

Related Q&A

73

FDA Expands Precision Oncology Approvals Across Hematologic and Solid Tumors : Oncol Times | May 2026

Introduction Recent FDA approvals continue to accelerate the shift toward biomarker-driven and targeted cancer therapy across hematologic malignancies and solid tumors. Novel immunotherapies and molecularly targeted agents are...

74

PD-(L)1 Plus Chemotherapy Benefits Advanced Gastric Cancer Across Regions : Clin Transl Gastroenterol | May 2026

Introduction Immune checkpoint inhibitors targeting programmed cell death protein-(ligand) 1 (PD-[L]1) have transformed first-line treatment of advanced gastric cancer (GC) and gastroesophageal junction cancer (GEJC). However, important regional...

75

Pancreatic Cancer Care Enters an Era of Biology-Guided Precision Management : Nat Rev Dis Primers | May 2026

Introduction Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal human malignancies, characterized by aggressive tumor biology, late-stage diagnosis and limited long-term survival. Despite decades of therapeutic...

76

COLOSOTO Trial Explores Chemotherapy-Sparing KRAS G12C Strategy in Frail Metastatic Colorectal Cancer : Digestive and Liver Disease | May 2026

Introduction KRAS G12C mutations represent a clinically important molecular subtype of metastatic colorectal cancer (mCRC), occurring in approximately 3–4% of cases and often associated with aggressive disease biology...

77

Molecular Tumor Boards Improve Survival in Refractory Solid Tumors : The Oncologist | May 2026

Introduction Precision oncology has transformed cancer care through the integration of genomic profiling and targeted therapies. However, translating complex next-generation sequencing data into clinically actionable treatment strategies remains...

78

Pan-RAS Inhibition with Daraxonrasib Shows Promising Activity in Advanced Pancreatic Cancer | New England Journal of Medicine

Introduction Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited survival gains despite advances in systemic therapy. More than 90% of PDAC tumors harbor...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer